以下内容由博览财经提供，不代表浙商证券认同或赞成其观点、不构成任何投资建议；据此操作，盈亏自负；市场有风险，投资需谨慎。创新药迎催化：国家医保局发布了《商业健康保险创新药品目录（2025年）》（以下简称商保创新药目录），提出多项利于商保创新药目录内药品放量的措施。与此同时，机构普遍看好创新药板块估值修复潜力，逻辑在于：（1）商保创新药目录发布，持续拓宽医保支付端空间；（2）出海已成趋势，中国或重新...
Source Link以下内容由博览财经提供，不代表浙商证券认同或赞成其观点、不构成任何投资建议；据此操作，盈亏自负；市场有风险，投资需谨慎。创新药迎催化：国家医保局发布了《商业健康保险创新药品目录（2025年）》（以下简称商保创新药目录），提出多项利于商保创新药目录内药品放量的措施。与此同时，机构普遍看好创新药板块估值修复潜力，逻辑在于：（1）商保创新药目录发布，持续拓宽医保支付端空间；（2）出海已成趋势，中国或重新...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.